Reported 12 months ago
At a forum on June 28, 2024, the potential and application prospects of exosomes in medicine were highlighted by Dr. Kim Seong-Hun, the founder of Zymedi from South Korea. Dr. Kim shared insights on the secretion of a novel bioactive protein by exosomes - Aminoacyl-tRNA synthetases (ARS), which impact biomedical and cosmetic applications. Different ARS enzymes are found to be secreted in specific cells or stress environments, playing roles in various physiological processes like angiogenesis, immune regulation, wound healing, and stem cell activation. Three new drugs utilizing this technology are currently in clinical trials for treating diseases like pulmonary arterial hypertension and pulmonary fibrosis. Collaboration opportunities in exosome technology development with Taiwan companies were noted, along with advancements in cell reprogramming and regeneration techniques. The potential for using exosomes derived from mesenchymal stem cells to reduce eye inflammation and promote corneal repair was also discussed, offering new treatment possibilities for dry eye syndrome patients. The importance of close cooperation and resource integration in Taiwan's exosome research and industrialization process was emphasized by Prof. Li Cai-Kun, the deputy executive director of the Biotechnology Center.
Source: YAHOO